PURPOSE: Susceptibility-weighted imaging (SWI) has significantly increased our sensitivity in detecting hemorrhagic brain lesions. We sought to explore the prevalence of intratumoral hemorrhage as detected by SWI in brain metastases from melanoma and breast cancer. METHODS: Lesions with a size of 0.1 cm were categorized as micrometastases, whereas larger lesions were categorized as macrometastases. Susceptibility-weighted imaging findings on locations corresponding to enhancing lesions were categorized as either positive or negative based on presence/absence of signal dropout. The percentage of SWI positivity was then estimated as a function of lesion size. Two-tailed Fisher exact test was performed to examine differences in the contingency tables. RESULTS: Magnetic resonance imaging studies from 73 patients with 1173 brain metastases, which enhanced on postcontrast T1-weighted imaging (T1WI) were selected for analysis. Of these lesions, 952 had SWI data available, and 342 of 952 were micrometastases. Only 10 of the 342 micrometastases and 410 (67.2%) of the 610 macrometastases were SWI positive (P < 0.0001). When examined by tumor type, 76.9% (melanoma) versus 55.6% (breast cancer) were SWI positive (P < 0.0001), regardless of tumor size. All melanoma lesions (8/8) and only 1 of 15 breast cancer lesions larger than 1.5 cm were SWI positive. CONCLUSION: With the use of combined SWI and contrast-enhanced high-resolution T1 imaging, we found that presence of intratumoral brain hemorrhage is uncommon in micrometastases but common in metastases greater than 0.1 cm from breast cancer or melanoma. Large metastases commonly harbored hemorrhage, and this occurred more frequently in patients with melanoma than with breast cancer.
PURPOSE: Susceptibility-weighted imaging (SWI) has significantly increased our sensitivity in detecting hemorrhagic brain lesions. We sought to explore the prevalence of intratumoral hemorrhage as detected by SWI in brain metastases from melanoma and breast cancer. METHODS: Lesions with a size of 0.1 cm were categorized as micrometastases, whereas larger lesions were categorized as macrometastases. Susceptibility-weighted imaging findings on locations corresponding to enhancing lesions were categorized as either positive or negative based on presence/absence of signal dropout. The percentage of SWI positivity was then estimated as a function of lesion size. Two-tailed Fisher exact test was performed to examine differences in the contingency tables. RESULTS: Magnetic resonance imaging studies from 73 patients with 1173 brain metastases, which enhanced on postcontrast T1-weighted imaging (T1WI) were selected for analysis. Of these lesions, 952 had SWI data available, and 342 of 952 were micrometastases. Only 10 of the 342 micrometastases and 410 (67.2%) of the 610 macrometastases were SWI positive (P < 0.0001). When examined by tumor type, 76.9% (melanoma) versus 55.6% (breast cancer) were SWI positive (P < 0.0001), regardless of tumor size. All melanoma lesions (8/8) and only 1 of 15 breast cancer lesions larger than 1.5 cm were SWI positive. CONCLUSION: With the use of combined SWI and contrast-enhanced high-resolution T1 imaging, we found that presence of intratumoral brain hemorrhage is uncommon in micrometastases but common in metastases greater than 0.1 cm from breast cancer or melanoma. Large metastases commonly harbored hemorrhage, and this occurred more frequently in patients with melanoma than with breast cancer.
Authors: Vivek Sehgal; Zachary Delproposto; E Mark Haacke; Karen A Tong; Nathaniel Wycliffe; Daniel K Kido; Yingbiao Xu; Jaladhar Neelavalli; Djamel Haddar; Jürgen R Reichenbach Journal: J Magn Reson Imaging Date: 2005-10 Impact factor: 4.813
Authors: D Kondziolka; M Bernstein; L Resch; C H Tator; J F Fleming; R G Vanderlinden; H Schutz Journal: J Neurosurg Date: 1987-12 Impact factor: 5.115
Authors: Jie Chen; Jiule Ding; Yongming Dai; Wei Xing; Jun Sun; Zishu Zhang; Yang Xuan; Vasuki Pilli; E Mark Haacke; Jiani Hu Journal: PLoS One Date: 2013-06-06 Impact factor: 3.240
Authors: Salil Soman; Jose A Bregni; Berkin Bilgic; Ursula Nemec; Audrey Fan; Zhe Liu; Robert L Barry; Jiang Du; Keith Main; Jerome Yesavage; Maheen M Adamson; Michael Moseley; Yi Wang Journal: Curr Radiol Rep Date: 2017-02-14
Authors: Timothy J Kaufmann; Marion Smits; Jerrold Boxerman; Raymond Huang; Daniel P Barboriak; Michael Weller; Caroline Chung; Christina Tsien; Paul D Brown; Lalitha Shankar; Evanthia Galanis; Elizabeth Gerstner; Martin J van den Bent; Terry C Burns; Ian F Parney; Gavin Dunn; Priscilla K Brastianos; Nancy U Lin; Patrick Y Wen; Benjamin M Ellingson Journal: Neuro Oncol Date: 2020-06-09 Impact factor: 12.300
Authors: Katerina Deike-Hofmann; Daniel Thünemann; Michael O Breckwoldt; Daniel Schwarz; Alexander Radbruch; Alexander Enk; Martin Bendszus; Jessica Hassel; Heinz-Peter Schlemmer; Philipp Bäumer Journal: PLoS One Date: 2018-03-29 Impact factor: 3.240
Authors: Motaz Hamed; Niklas Schäfer; Christian Bode; Valeri Borger; Anna-Laura Potthoff; Lars Eichhorn; Frank A Giordano; Erdem Güresir; Muriel Heimann; Yon-Dschun Ko; Jennifer Landsberg; Felix Lehmann; Alexander Radbruch; Elisa Scharnböck; Christina Schaub; Katjana S Schwab; Johannes Weller; Ulrich Herrlinger; Hartmut Vatter; Patrick Schuss; Matthias Schneider Journal: Front Oncol Date: 2021-09-14 Impact factor: 6.244